Immunovant, Inc.

IMVTNASDAQHealthcareBiotechnology

$28.41- (-)1Y +55.28%

As of Oct 23, 2026 close

Market cap: $5.84B
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $18.51$45.42
Volume (live): -
Avg. volume (3M): 1.57M

Immunovant, Inc. (IMVT) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Immunovant, Inc. stock.

Analyst Consensus Rating

Investment consensus from 13 professional research analysts

Consensus Rating

Buy

Based on 13 unique analysts

(14 total ratings in last 90 days)

High Confidence∞:1 Buy/Sell

Average Price Target

$48.80

+71.77% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest IMVT Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 20, 2026	Edmund Ingham	Forbes	Initiates Coverage	Hold	-
Oct 16, 2026	Derek Archila	Wells Fargo	Maintains	Buy	$45.00
Oct 12, 2026	Dina Ramadane	BofA Securities	Maintains	Buy	$45.00
Sep 26, 2026	Sam Slutsky	LifeSci Capital	Maintains	Buy	$53.00
Sep 26, 2026	Eve Burstein	Bernstein	Maintains	Hold	$37.00
Sep 24, 2026	Danielle Brill	Truist	Maintains	Hold	-
Sep 24, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Hold	-
Sep 23, 2026	Douglas Tsao	HC Wainwright	Maintains	Buy	$41.00
Sep 21, 2026	Yasmeen Rahimi	Piper Sandler	Maintains	Buy	$66.00
Aug 24, 2026	Unknown Analyst	UBS	Reiterates	Hold	$24.00 → $40.00 +16.00 (+66.7%)
Aug 11, 2026	Alex Thompson CFA	Stifel Nicolaus	Maintains	Buy	$49.00 → $57.00 +8.00 (+16.3%)
Aug 10, 2026	Brian Cheng	JP Morgan	Maintains	Buy	$50.00
Aug 7, 2026	Dina Ramadane	BofA Securities	Reiterates	Buy	$43.00 → $45.00 +2.00 (+4.7%)
Aug 7, 2026	Leland Gershell	Oppenheimer	Reiterates	Buy	$54.00

Edmund Ingham

Forbes

HoldInitiates Coverage

Oct 20

Derek Archila

Wells Fargo

BuyMaintains

$45.00

Oct 16

Dina Ramadane

BofA Securities

BuyMaintains

$45.00

Oct 12

Sam Slutsky

LifeSci Capital

BuyMaintains

$53.00

Sep 26

Eve Burstein

Bernstein

HoldMaintains

$37.00

Sep 26

Danielle Brill

Truist

HoldMaintains

Sep 24

Zacks Equity Research

HoldInitiates Coverage

Sep 24

Douglas Tsao

HC Wainwright

BuyMaintains

$41.00

Sep 23

Yasmeen Rahimi

Piper Sandler

BuyMaintains

$66.00

Sep 21

Unknown Analyst

UBS

HoldReiterates

$24.00 → $40.00

Aug 24

Alex Thompson CFA

Stifel Nicolaus

BuyMaintains

$49.00 → $57.00

Aug 11

Brian Cheng

JP Morgan

BuyMaintains

$50.00

Aug 10

Dina Ramadane

BofA Securities

BuyReiterates

$43.00 → $45.00

Aug 7

Leland Gershell

Oppenheimer

BuyReiterates

$54.00

Aug 7

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 20, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for IMVT?

The analyst consensus rating for IMVT is Buy, based on the latest ratings from 13 analysts over the last 90 days.

What is the average price target for IMVT?

The average 12-month price target for IMVT is $48.80, representing an upside of 71.8% from the Oct 23, 2026 close of $28.41.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.